{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=FVIII&page=10",
    "query": {
      "intervention": "FVIII",
      "page": 10
    },
    "page_size": 10
  },
  "pagination": {
    "page": 10,
    "page_size": 10,
    "total_count": 250,
    "total_pages": 25,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=FVIII&page=11&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=FVIII&page=9&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-19T01:11:51.050Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02830477",
      "title": "Study Evaluating \"Real World\" Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog Alfa) for Routine Prophylaxis",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hemophilia A, Congenital"
      ],
      "interventions": [
        {
          "name": "Kovaltry (Antihemophilic Factor [Recombinant], BAY81-8973",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "MALE",
        "summary": "Male only"
      },
      "enrollment_count": 313,
      "start_date": "2016-10-14",
      "completion_date": "2021-03-01",
      "has_results": false,
      "last_update_posted_date": "2023-11-07",
      "last_synced_at": "2026-10-19T01:11:51.050Z",
      "location_count": 13,
      "location_summary": "Mobile, Alabama • Aurora, Colorado • Gainesville, Florida + 10 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Pensacola",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02830477"
    },
    {
      "nct_id": "NCT00936845",
      "title": "Females With Severe or Moderate Hemophilia A or B: A Multi-Center Study",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hemophilia A",
        "Hemophilia B"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Weill Medical College of Cornell University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "1 Month and older · Female only"
      },
      "enrollment_count": 22,
      "start_date": "2005-04",
      "completion_date": "2010-01",
      "has_results": false,
      "last_update_posted_date": "2012-12-10",
      "last_synced_at": "2026-10-19T01:11:51.050Z",
      "location_count": 18,
      "location_summary": "Duarte, California • Aurora, Colorado • Washington D.C., District of Columbia + 15 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00936845"
    },
    {
      "nct_id": "NCT00331006",
      "title": "Rituximab to Treat Severe Hemophilia A",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "Rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Carelon Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Months and older"
      },
      "enrollment_count": 23,
      "start_date": "2006-06",
      "completion_date": "2012-01",
      "has_results": true,
      "last_update_posted_date": "2013-06-11",
      "last_synced_at": "2026-10-19T01:11:51.050Z",
      "location_count": 13,
      "location_summary": "Orange, California • Atlanta, Georgia • Chicago, Illinois + 10 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00331006"
    },
    {
      "nct_id": "NCT01712438",
      "title": "Human Cell Line-derived Recombinant Factor VIII (Human-cl-rhFVIII) in Previously Untreated Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Severe Hemophilia A"
      ],
      "interventions": [
        {
          "name": "Human cl rhFVIII",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Octapharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "MALE",
        "summary": "Male only"
      },
      "enrollment_count": 110,
      "start_date": "2013-02",
      "completion_date": "2019-12-20",
      "has_results": true,
      "last_update_posted_date": "2021-01-19",
      "last_synced_at": "2026-10-19T01:11:51.050Z",
      "location_count": 3,
      "location_summary": "Sacramento, California • St. Petersburg, Florida • Boston, Massachusetts",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01712438"
    },
    {
      "nct_id": "NCT07416526",
      "title": "A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "NXT007",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Human Coagulation Factor VIII",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT",
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 138,
      "start_date": "2026-05-15",
      "completion_date": "2031-09-23",
      "has_results": false,
      "last_update_posted_date": "2026-09-23",
      "last_synced_at": "2026-10-19T01:11:51.050Z",
      "location_count": 2,
      "location_summary": "Aurora, Colorado • Iowa City, Iowa",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07416526"
    },
    {
      "nct_id": "NCT03061201",
      "title": "A Study of Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 (PF-07055480) in Subjects With Severe Hemophilia A",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "SB-525 (PF-07055480)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 13,
      "start_date": "2017-06-21",
      "completion_date": "2024-07-16",
      "has_results": true,
      "last_update_posted_date": "2025-09-30",
      "last_synced_at": "2026-10-19T01:11:51.050Z",
      "location_count": 22,
      "location_summary": "Little Rock, Arkansas • Duarte, California • Sacramento, California + 7 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03061201"
    },
    {
      "nct_id": "NCT02615691",
      "title": "A Study of PEGylated Recombinant Factor VIII (BAX855) in Previously Untreated Young Children With Severe Hemophilia A",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "PEGylated Recombinant Factor VIII",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ITI",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baxalta now part of Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "5 Years",
        "sex": "ALL",
        "summary": "Up to 5 Years"
      },
      "enrollment_count": 120,
      "start_date": "2015-11-12",
      "completion_date": "2024-10-29",
      "has_results": true,
      "last_update_posted_date": "2025-07-28",
      "last_synced_at": "2026-10-19T01:11:51.050Z",
      "location_count": 20,
      "location_summary": "Phoenix, Arizona • Cupertino, California • Oakland, California + 17 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Cupertino",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Roseville",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02615691"
    },
    {
      "nct_id": "NCT03876301",
      "title": "Lead-in Study to Collect Prospective Efficacy and Safety Data of Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Participants",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Blood Coagulation Disorder",
        "Blood Coagulation Disorders, Inherited",
        "Coagulation Protein Disorders",
        "Hemophilia A",
        "Genetic Diseases, Inborn",
        "Genetic Diseases, X-Linked",
        "Hematologic Diseases",
        "Hemorrhagic Disorders",
        "Factor VIII Deficiency"
      ],
      "interventions": [
        {
          "name": "Standard of Care FVIII Replacement therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Spark Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 25,
      "start_date": "2019-01-21",
      "completion_date": "2023-05-02",
      "has_results": false,
      "last_update_posted_date": "2023-07-10",
      "last_synced_at": "2026-10-19T01:11:51.050Z",
      "location_count": 6,
      "location_summary": "San Francisco, California • Gainesville, Florida • Atlanta, Georgia + 3 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Madison",
          "state": "Mississippi"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03876301"
    },
    {
      "nct_id": "NCT00157053",
      "title": "Study of Pharmacokinetics, Efficacy and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients - A Continuation of Clinical Study 069901",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "Antihemophilic factor, recombinant, manufactured protein-free",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Baxalta now part of Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "10 Years and older · Male only"
      },
      "enrollment_count": 82,
      "start_date": "2001-11-22",
      "completion_date": "2004-08-03",
      "has_results": false,
      "last_update_posted_date": "2021-08-24",
      "last_synced_at": "2026-10-19T01:11:51.050Z",
      "location_count": 11,
      "location_summary": "Aurora, Colorado • Atlanta, Georgia • Peoria, Illinois + 7 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "East Lansing",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00157053"
    },
    {
      "nct_id": "NCT02048111",
      "title": "Study of Recombinant Factor IX Product, IB1001, in Previously Treated Subjects With Hemophilia B",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hemophilia B"
      ],
      "interventions": [
        {
          "name": "IB1001",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Cangene Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2014-03",
      "completion_date": "2015-11",
      "has_results": false,
      "last_update_posted_date": "2016-08-23",
      "last_synced_at": "2026-10-19T01:11:51.050Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02048111"
    }
  ]
}